Board of Trustees of The Leland Stanford Junior University’s Unicycive Therapeutics UNCY Stock Holding History

Board of Trustees of The Leland Stanford Junior University’s Portfolio UNCY Stock Details UNCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,302	Closed	-$34K	–	40
2022 Q4	$34K	Hold	6,302	–	–	﹤0.01%	33
2022 Q3	$37K	Sell	6,302 -18,456	-75%	-$135K	﹤0.01%	51
2022 Q2	$205K	Hold	24,758	–	–	0.01%	30
2022 Q1	$319K	Hold	24,758	–	–	0.02%	33
2021 Q4	$510K	Hold	24,758	–	–	0.03%	27
2021 Q3	$700K	Buy	+24,758	New	+$710K	0.05%	27

Other funds holding UNCY

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

TCM

Tandem Capital Management Woodcliff Lake, New Jersey $238M AUM 38.59% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Oxbow Advisors Austin, Texas $1.23B AUM 23.59% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University's UNCY Position: Q1 2023 in Review

Board of Trustees of The Leland Stanford Junior University sold out of Unicycive Therapeutics (UNCY) in Q1 2023, closing a stake of 6,302 shares — an estimated $34K sold.

Board of Trustees of The Leland Stanford Junior University first reported a position in UNCY in Q3 2021 and held it in 6 quarters. The position peaked at $700K in Q3 2021. 12 funds tracked by Wall St. Rank hold UNCY as of Q1 2023.

Board of Trustees of The Leland Stanford Junior University reported no remaining Unicycive Therapeutics position as of Q1 2023 after selling out during the quarter.
Board of Trustees of The Leland Stanford Junior University sold 6,302 Unicycive Therapeutics shares in Q1 2023, an estimated $34K.
Board of Trustees of The Leland Stanford Junior University first reported a position in Unicycive Therapeutics in Q3 2021 and held it in 6 quarters.
Board of Trustees of The Leland Stanford Junior University's Unicycive Therapeutics position peaked at $700K in Q3 2021.
12 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2023.

Based on Board of Trustees of The Leland Stanford Junior University's 13F filing for Q1 2023, filed 15 May 2023.